We are live on ! Find out more
APTO

Aptose Biosciences

Delisted

APTO was delisted on the 1st of April, 2025.

25 hedge funds and large institutions have $3.25M invested in Aptose Biosciences in 2023 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

193% more capital inflows, than outflows

Capital inflows: $807K | Capital outflows: $275K

33% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 3

4% more funds holding

Funds holding: 24 → 25 (+1)

1.67% more ownership

Funds ownership: 16.08% → 17.75% (+1.7%)

25% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 4

Holders
25
Holders Change
+1
Holders Change %
+4.17%
% of All Funds
0.4%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
3
Reduced
4
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

APTO Hedge Fund Activity: Q3 2023 in Review

25 of the 6,318 institutional investors tracked by Wall St. Rank reported a position in Aptose Biosciences (APTO) for Q3 2023, worth a combined $3.25M — down 31% from $4.71M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new APTO positions and 3 closed out — a net gain of 1 holder — while 3 added to existing stakes and 4 trimmed.

The largest buyer was Sigma Planning, opening a new position worth an estimated $573K. The largest seller was Goldman Sachs, exiting entirely with an estimated $165K sold.

  • 25 institutional investors held Aptose Biosciences (APTO) as of Q3 2023, up from 24 in Q2 2023.
  • Funds reported $3.25M of Aptose Biosciences stock for Q3 2023, down 31% quarter-over-quarter.
  • 4 funds opened new Aptose Biosciences positions in Q3 2023 and 3 closed out, a net change of +1 holder.
  • The largest Aptose Biosciences buyer in Q3 2023 was Sigma Planning, an estimated $573K added.
  • The largest Aptose Biosciences seller in Q3 2023 was Goldman Sachs, an estimated $165K sold.

Based on aggregated 13F filings for Q3 2023.